News

Siponimod Feedback Survey

  • Announcement

Have your say on this topic by completing the MS Society of Canada survey below.

The Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d’excellence en santé et en services sociaux (INESSS) are conducting a drug review for an MS treatment called Mayzent (siponimod), for the management of adults with secondary progressive multiple sclerosis.

We’re providing input on behalf of people affected by SPMS to CADTH and INESSS, so we need to hear from you. This is your opportunity to have your voice heard about public coverage of MS medications and the impact of medications on your quality of life. You don’t have to be taking or have taken siponimod to participate. Please fill out this short survey.

Open navigation